Frontiers in Genetics (Dec 2022)
TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics study
- Yuting Tao,
- Yuting Tao,
- Yuting Tao,
- Yuting Tao,
- Xia Li,
- Xia Li,
- Xia Li,
- Xia Li,
- Yushan Zhang,
- Yushan Zhang,
- Yushan Zhang,
- Yushan Zhang,
- Liangyu He,
- Liangyu He,
- Liangyu He,
- Qinchen Lu,
- Qinchen Lu,
- Qinchen Lu,
- Qinchen Lu,
- Yaobang Wang,
- Yaobang Wang,
- Lixin Pan,
- Lixin Pan,
- Lixin Pan,
- Lixin Pan,
- Zhenxing Wang,
- Zhenxing Wang,
- Chao Feng,
- Chao Feng,
- Chao Feng,
- Chao Feng,
- Yuanliang Xie,
- Yuanliang Xie,
- Yuanliang Xie,
- Zhiyong Lai,
- Zhiyong Lai,
- Tianyu Li,
- Tianyu Li,
- Tianyu Li,
- Zhong Tang,
- Zhong Tang,
- Zhong Tang,
- Qiuyan Wang,
- Qiuyan Wang,
- Xi Wang,
- Xi Wang
Affiliations
- Yuting Tao
- Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China
- Yuting Tao
- Key Laboratory of Biological Molecular Medicine Research, Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Nanning, China
- Yuting Tao
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Yuting Tao
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Xia Li
- Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China
- Xia Li
- Key Laboratory of Biological Molecular Medicine Research, Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Nanning, China
- Xia Li
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Xia Li
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Yushan Zhang
- Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China
- Yushan Zhang
- Key Laboratory of Biological Molecular Medicine Research, Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Nanning, China
- Yushan Zhang
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Yushan Zhang
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Liangyu He
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Liangyu He
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Liangyu He
- Departments of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Qinchen Lu
- Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China
- Qinchen Lu
- Key Laboratory of Biological Molecular Medicine Research, Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Nanning, China
- Qinchen Lu
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Qinchen Lu
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Yaobang Wang
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Yaobang Wang
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Lixin Pan
- Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China
- Lixin Pan
- Key Laboratory of Biological Molecular Medicine Research, Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Nanning, China
- Lixin Pan
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Lixin Pan
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Zhenxing Wang
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Zhenxing Wang
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Chao Feng
- Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China
- Chao Feng
- Key Laboratory of Biological Molecular Medicine Research, Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Nanning, China
- Chao Feng
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Chao Feng
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Yuanliang Xie
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Yuanliang Xie
- Departments of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Yuanliang Xie
- Department of Urology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China
- Zhiyong Lai
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Zhiyong Lai
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Tianyu Li
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Tianyu Li
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Tianyu Li
- Departments of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Zhong Tang
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Zhong Tang
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Zhong Tang
- School of Information and Management, Guangxi Medical University, Nanning, China
- Qiuyan Wang
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Qiuyan Wang
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- Xi Wang
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Xi Wang
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China
- DOI
- https://doi.org/10.3389/fgene.2022.1057302
- Journal volume & issue
-
Vol. 13
Abstract
Background: The tumor suppressor gene TP53 is frequently mutated or inactivated in bladder cancer (BLCA), which is implicated in the pathogenesis of tumor. However, the cellular mechanisms of TP53 mutations are complicated, yet well-defined, but their clinical prognostic value in the management of BLCA remains controversial. This study aimed to explore the role of TP53 mutation in regulating the tumor microenvironment (TME), elucidate the effects of TP53 activity on BLCA prognosis and immunotherapy response.Methods: A TP53-related signature based on TP53-induced and TP53-repressed genes was used to construct a TP53 activity-related score and classifier. The abundance of different immune cell types was determined using CIBERSORT to estimate immune cell infiltration. Moreover, the heterogeneity of the tumor immune microenvironment between the high and low TP53 score groups was further evaluated using single-cell mass cytometry (CyTOF) and imaging mass cytometry (IMC). Moreover, pathway enrichment analysis was performed to explore the differential biological functions between tumor epithelial cells with high and low TP53 activity scores. Finally, the receptor–ligand interactions between immune cells and tumor epithelial cells harboring distinct TP53 activity were analyzed by single-cell RNA-sequencing.Results: The TP53 activity-related gene signature differentiated well between TP53 functional retention and inactivation in BLCA. BLCA patients with low TP53 scores had worse survival prognosis, more TP53 mutations, higher grade, and stronger lymph node metastasis than those with high TP53 scores. Additionally, CyTOF and IMC analyses revealed that BLCA patients with low TP53 scores exhibited a potent immunosuppressive TME. Consistently, single-cell sequencing results showed that tumor epithelial cells with low TP53 scores were significantly associated with high cell proliferation and stemness abilities and strongly interacted with immunosuppressive receptor–ligand pairs.Conclusion: BLCA patients with low TP53 scores have a worse prognosis and a more immunosuppressive TME. This TP53 activity-related signature can serve as a potential prognostic signature for predicting the immune response, which may facilitate the development of new strategies for immunotherapy in BLCA.
Keywords